<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638920</url>
  </required_header>
  <id_info>
    <org_study_id>BASEC-Nr. 2020-01954</org_study_id>
    <nct_id>NCT04638920</nct_id>
  </id_info>
  <brief_title>Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy</brief_title>
  <acronym>TripleEX</acronym>
  <official_title>Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy (TripleEX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Malcolm Kohler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deep Breath Initiative (DBI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determination of specific molecular breath patterns by secondary electrospray ionisation mass&#xD;
      spectrometry (SESIHRMS) during and 8 weeks after a COPD exacerbation. Furthermore, breath&#xD;
      patterns will be assessed for correlation and association to clinical outcomes and treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exhaled breath metabolites</measure>
    <time_frame>twice during 8 weeks</time_frame>
    <description>Change in exhaled breath metabolites during vs after COPD exacerbation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>twice during 8 weeks</time_frame>
    <description>Correlation of breath metabolites with symtpoms (mMRC and CAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>twice during 8 weeks</time_frame>
    <description>Correlation of breath metabolites with CRP, eosinophils, exhaled NO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Causative agents</measure>
    <time_frame>twice during 8 weeks</time_frame>
    <description>Correlation of breath metabolites with sputum microbiology and viral swabs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment</measure>
    <time_frame>twice during 8 weeks</time_frame>
    <description>Correlation of breath metabolites with inhalational durgs, steroids, antibiotics</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COPD Exacerbation</condition>
  <arm_group>
    <arm_group_label>Exacerbators</arm_group_label>
    <description>Patients with COPD exacerbation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Exacerbators</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with COPD (staged according to GOLD recommendations, aged ≥18 years) on adherent&#xD;
        triple inhalational therapy, hospitalized due to COPD exacerbation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  age &gt;= 18 years&#xD;
&#xD;
          -  staged according to GOLD recommendations&#xD;
&#xD;
          -  GOLD stage 2-4, risk groups A-D&#xD;
&#xD;
          -  hospitalization due to COPD exacerbation&#xD;
&#xD;
          -  subjects adherent to triple inhalational therapy (beta-2-sympathomimetics,&#xD;
             anticholinergics, steroids)&#xD;
&#xD;
          -  suitable for follow-up assessment&#xD;
&#xD;
          -  &lt;48 hours after initiation of antibiotic therapy or systemic steroid therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  physical or intellectual impairment precluding informed consent or protocol adherence&#xD;
&#xD;
          -  known pregnancy&#xD;
&#xD;
          -  congenital defects with direct impact on central metabolism e.g. amino acid metabolism&#xD;
             defect&#xD;
&#xD;
          -  uncontrolled diabetes (e.g. HbA1c &gt;11% or Glc &gt;20mmol/l).&#xD;
&#xD;
          -  acute or chronic pulmonary disease other than COPD&#xD;
&#xD;
          -  renal failure or renal replacement therapy (GFR &lt; 15 mL/min)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Malcolm Kohler, MD</last_name>
    <phone>+41 44 255 38 28</phone>
    <email>malcolm.kohler@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felix Schmidt, MSc</last_name>
    <phone>+41 44 255 48 01</phone>
    <email>felix.schmidt@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <state>Zurich</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malcolm Kohler, MD</last_name>
      <phone>+41442553828</phone>
      <email>malcolm.kohler@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Felix Schmidt, MSc</last_name>
      <phone>+41442554801</phone>
      <email>felix.schmidt@usz.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Malcolm Kohler</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Exhaled breath analysis</keyword>
  <keyword>Mass spectrometry</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

